Survey of oncologists finds knowledge gap on medical marijuana
As more states legalize medical marijuana, two key groups — researchers whose job is it to understand its benefits and drawbacks, and physicians charged with advising potential users — are struggling to catch up with policymakers.
Ilana Braun, an assistant professor of psychiatry at Harvard Medical School and chief of the division of adult psychosocial oncology at the Dana-Farber Cancer Institute, led a survey of cancer physicians around the country, exploring their attitudes and actions on medical marijuana.
The survey was sent to 400 oncologists, with a 63 percent response rate. We asked Braun to outline her findings, which were published last month in the Journal of Clinical Oncology.
Stories you may be interested in
Medical marijuana helped elderly with chronic pain and reduced their use of opioids, study found
Your grandparents’ chronic aches and pains might best be eased with a little weed, a new study suggests. Not only did folks over 75 who took medical marijuana report less pain, their use of pot-based capsules, tinctures and e-cigarettes allowed a third of these patients to reduce their use of opioid painkillers, researchers found. “Medical marijuana, in…
Read More 
Data Migration and Mapping Functions
Medical software does not have a good reputation for user experience and intuitive design. It can seem like a full-time job just learning how to use these software solutions. In fact, according to a study from Stanford Medicine, 74% of doctors responded that their EMR increased the number of hours they work every day and…
Read More 
COVID-19 and medical cannabis patients: What you need to know
In the midst of the COVID-19 maelstrom, the recent shuttering of nonessential stores has created concern around access to cannabis, particularly for medicinal cannabis consumers. Those who depend on cannabis for therapeutic purposes will be relieved to learn that across the US, medical cannabis dispensaries have been deemed essential services, comparable to pharmacies. As of March…
Read More 
Thanks to the Farm Bill, Hemp Is Legal. Here’s What It Means for CBD.
On Tuesday, the Senate voted to approve a new an $867 billion farm bill, and on Wednesday, it passed in Congress. While the bill has plenty of positive merits, the one people are perhaps most excited about is the fact that it will legalize the production, sale, and distribution of industrial hemp at a federal…
Read More 
Unstructured EHR data more useful for predictive analytics, study shows
A new report in the Journal of the American Medical Informatics Association has shown that real-world data contained in unstructured narratives has big predictive value when it comes to clinical research. WHY IT MATTERSWhile structured clinical notes in the electronic health record have obvious value, the research in JAMIA suggests that real-world data captured in unstructured notes…
Read More 
Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease
A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More